Princeton Capital Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $391K | Sell |
10,643
-47
| -0.4% | -$2.23K | 0.11% | 89 |
|
|
2025
Q4 | $544K | Sell |
10,690
-4,386
| -29% | -$224K | 0.14% | 67 |
|
|
2025
Q3 | $837K | Sell |
15,076
-1,917
| -11% | -$112K | 0.22% | 51 |
|
|
2025
Q2 | $1.17M | Sell |
16,993
-8,675
| -34% | -$590K | 0.35% | 44 |
|
|
2025
Q1 | $1.78M | Sell |
25,668
-22,619
| -47% | -$1.87M | 0.63% | 26 |
|
|
2024
Q4 | $4.15M | Sell |
48,287
-753
| -2% | -$81.4K | 1.29% | 16 |
|
|
2024
Q3 | $5.84M | Buy |
49,040
+183
| +0.4% | +$24.4K | 1.84% | 13 |
|
|
2024
Q2 | $6.97M | Buy |
48,857
+342
| +0.7% | +$45.3K | 2.27% | 10 |
|
|
2024
Q1 | $6.23M | Buy |
48,515
+453
| +0.9% | +$53.9K | 2.25% | 11 |
|
|
2023
Q4 | $4.97M | Buy |
48,062
+2,806
| +6% | +$277K | 2% | 15 |
|
|
2023
Q3 | $4.12M | Sell |
45,256
-9,454
| -17% | -$833K | 1.9% | 14 |
|
|
2023
Q2 | $4.43M | Sell |
54,710
-1,478
| -3% | -$121K | 1.84% | 18 |
|
|
2023
Q1 | $4.47M | Sell |
56,188
-6,808
| -11% | -$483K | 1.91% | 16 |
|
|
2022
Q4 | $4.26M | Sell |
62,996
-8,034
| -11% | -$471K | 1.89% | 16 |
|
|
2022
Q3 | $3.54M | Buy |
71,030
+350
| +0.5% | +$18.8K | 1.55% | 20 |
|
|
2022
Q2 | $3.94M | Buy |
70,680
+1,610
| +2% | +$89.3K | 1.53% | 19 |
|
|
2022
Q1 | $3.83M | Sell |
69,070
-18
| -0% | -$924 | 1.19% | 25 |
|
|
2021
Q4 | $3.87M | Buy |
69,088
+288
| +0.4% | +$15.6K | 1.11% | 27 |
|
|
2021
Q3 | $3.3M | Sell |
68,800
-770
| -1% | -$37.2K | 1.05% | 29 |
|
|
2021
Q2 | $2.91M | Buy |
69,570
+1,432
| +2% | +$55.5K | 0.9% | 35 |
|
|
2021
Q1 | $2.3M | Sell |
68,138
-888
| -1% | -$31.6K | 0.78% | 39 |
|
|
2020
Q4 | $2.41M | Buy |
69,026
+2,468
| +4% | +$85.3K | 0.86% | 35 |
|
|
2020
Q3 | $2.31M | Buy |
66,558
+2,574
| +4% | +$85.8K | 0.93% | 33 |
|
|
2020
Q2 | $2.1M | Buy |
63,984
+1,270
| +2% | +$40.5K | 0.93% | 33 |
|
|
2020
Q1 | $1.94M | Sell |
62,714
-1,746
| -3% | -$52K | 1.01% | 33 |
|
|
2019
Q4 | $2.04M | Buy |
64,460
+124
| +0.2% | +$3.43K | 0.91% | 30 |
|
|
2019
Q3 | $1.66M | Sell |
64,336
-906
| -1% | -$22.9K | 0.81% | 33 |
|
|
2019
Q2 | $1.67M | Sell |
65,242
-850
| -1% | -$21K | 0.81% | 34 |
|
|
2019
Q1 | $1.73M | Sell |
66,092
-1,504
| -2% | -$37K | 0.87% | 31 |
|
|
2018
Q4 | $1.56M | Sell |
67,596
-28,450
| -30% | -$632K | 0.91% | 30 |
|
|
2018
Q3 | $2.26M | Sell |
96,046
-4,998
| -5% | -$122K | 0.94% | 29 |
|
|
2018
Q2 | $2.33M | Buy |
101,044
+560
| +0.6% | +$13.3K | 1.01% | 29 |
|
|
2018
Q1 | $2.47M | Sell |
100,484
-3,826
| -4% | -$100K | 1.1% | 29 |
|
|
2017
Q4 | $2.8M | Buy |
+104,310
| New | +$2.65M | 1.25% | 27 |
|
Other funds holding NVO
DAM
F
Princeton Capital Management's NVO Position: Q1 2026 in Review
Princeton Capital Management reduced its Novo Nordisk (NVO) stake by 0.44% in Q1 2026, selling an estimated $2.23K and leaving 10,643 shares worth $391K. The position accounts for 0.11% of the portfolio, ranked #89.
Princeton Capital Management first reported a position in NVO in Q4 2017 and has held it in 34 quarters since. The position peaked at $6.97M in Q2 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Princeton Capital Management held 10,643 shares of Novo Nordisk worth $391K as of Q1 2026.
- Princeton Capital Management sold 47 Novo Nordisk shares in Q1 2026, an estimated $2.23K.
- Novo Nordisk made up 0.11% of Princeton Capital Management's portfolio in Q1 2026, its #89 holding.
- Princeton Capital Management first reported a position in Novo Nordisk in Q4 2017 and has held it in 34 quarters since.
- Princeton Capital Management's Novo Nordisk position peaked at $6.97M in Q2 2024.
- 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Princeton Capital Management's 13F filing for Q1 2026, filed 8 May 2026.